Literature DB >> 28644700

Intermittent Ischemic Preconditioning Protects Against Hepatic Ischemia-Reperfusion Injury and Extensive Hepatectomy in Steatotic Rat Liver.

Nikolaos Sikalias1, Theodore Karatzas2, Konstantinos Alexiou1, Lamprini Mountzalia1, Maria Demonakou3, Ioannis D Kostakis2, Argyro Zacharioudaki4, Apostolos Papalois4, Gregory Kouraklis2.   

Abstract

BACKGROUND: Hepatic steatosis causes severe liver damage and has deleterious effects when associated with ischemia-reperfusion mechanisms. Ischemic preconditioning (IPC) protects lean liver against prolonged ischemia by improving micro-circulation and reducing lipid peroxidation. We investigated the effect of intermittent IPC on liver ischemia-reperfusion injury (IRI) and extensive hepatectomy in severe hepatic steatosis.
METHODS: Severe hepatic steatosis was performed by 12-14 weeks of choline-free diet in 108 Wistar rats. We induced 30-minute ischemia-reperfusion manipulations and extensive hepatectomy with or without prior IPC in steatotic livers and after 6 and 24 hours of reperfusion blood transaminases, and IL6, TNFα, NO and Lactate in blood and liver tissue were measured.
RESULTS: Steatotic rats subjected to hepatic ischemia-reperfusion alone after extensive hepatectomy, showed severe liver damage with significantly increased values of AST, ALT, TNFα and Lactate and significantly reduced IL6 and NO, while no one rat survived for more than 29 hours. On the contrary, steatotic rats subjected to intermittent IPC, 24 hours before ischemia-reperfusion, presented increased 30-day survival (67%), lower values of AST, ALT, TNFα and Lactate, and increased IL6 and NO levels. Simple and intermittent IPC manipulations, 1 hour before the IRI and extended hepatectomy, did not prolong survival more than 57 and 98 hours, respectively. Simple IPC, 24 hours before IRI and extended hepatectomy had the lowest possible survival (16.7%).
CONCLUSIONS: Hepatic steatosis and IRI after major liver surgery largely affect morbidity and mortality. Intermittent IPC, 24 hours before IRI and extensive hepatectomy, presents higher 30-day survival and improved liver function parameters.

Entities:  

Keywords:  extensive hepatectomy; fatty liver disease; intermittent ischemic preconditioning; ischemia-reperfusion injury; simple ischemic preconditioning; steatotic liver

Mesh:

Year:  2017        PMID: 28644700     DOI: 10.1080/08941939.2017.1334844

Source DB:  PubMed          Journal:  J Invest Surg        ISSN: 0894-1939            Impact factor:   2.533


  6 in total

1.  How Much Ischemia Can the Severely Steatotic Rat Liver Tolerate?

Authors:  Ioannis D Kostakis; Nikolaos Sikalias; Konstantinos Alexiou; Lamprini Mountzalia; Apostolos Papalois; Theodore Karatzas
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

2.  Impact of combined ischemic preconditioning and remote ischemic perconditioning on ischemia-reperfusion injury after liver transplantation.

Authors:  Ding-Yang Li; Wen-Tao Liu; Guang-Yi Wang; Xiao-Ju Shi
Journal:  Sci Rep       Date:  2018-12-19       Impact factor: 4.379

3.  Cyclin-dependent kinase inhibitors p21 and p27 function as critical regulators of liver regeneration following 90% hepatectomy in the rat.

Authors:  Nicolas Moniaux; Laurence Lacaze; Adélie Gothland; Alice Deshayes; Didier Samuel; Jamila Faivre
Journal:  World J Hepatol       Date:  2020-12-27

4.  Remote Ischemic Preconditioning Attenuates Hepatic Ischemia/Reperfusion Injury after Hemorrhagic Shock by Increasing Autophagy.

Authors:  Hao Zhou; Lin Li; Hao Sun; Hua Li; Yuxuan Wu; Xiaomin Zhang; Jinsong Zhang
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

5.  Isoflurane upregulates microRNA-9-3p to protect rats from hepatic ischemia-reperfusion injury through inhibiting fibronectin type III domain containing 3B.

Authors:  Haiyan Wang; Longlong Guo; Yang Wang; Shan Song
Journal:  Cell Cycle       Date:  2021-07-25       Impact factor: 5.173

6.  Histopathological changes and onset of severe hepatic steatosis in rats fed a choline-free diet.

Authors:  Theodore Karatzas; Nikolaos Sikalias; Dimitrios Mantas; Apostolos Papalois; Konstantinos Alexiou; Lamprini Mountzalia; Gregory Kouraklis
Journal:  Exp Ther Med       Date:  2018-06-29       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.